Pro Medicus Ltd stock (AU000000PME8): Medical imaging software leader with strong US exposure

Pro Medicus Ltd develops and supplies medical imaging software solutions, including its flagship Visage Imaging platform, which uses AI to enhance radiology workflows. The company has seen growing adoption in the US market, where it serves major healthcare networks. Recent expansions highlight its role in digital imaging for US investors tracking healthcare tech.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Pro Medicus Ltd: core business model

Pro Medicus Ltd specializes in advanced medical imaging software, with Visage Imaging as its core product. This platform enables fast, high-quality image viewing and AI-assisted diagnostics for radiologists. Listed on the ASX under ticker PME, the company generates revenue primarily through perpetual licenses and annual support fees, according to its investor relations page as of 13.05.2026.

The business model emphasizes recurring revenue from maintenance contracts, which account for a significant portion of income. Pro Medicus targets large hospital networks and radiology groups, differentiating via superior image streaming technology that outperforms legacy PACS systems.

Main revenue and product drivers for Pro Medicus Ltd

Key products include Visage 7, a diagnostic viewer with AI integration for lesion detection and workflow automation. Revenue growth stems from US contracts with elite institutions, driven by demand for efficient radiology amid rising imaging volumes. In FY2023 results published in August 2023, annual contract value rose 28%, per company reports.

Subscription models and expansions into AI tools like voice recognition bolster drivers. US market penetration is critical, representing over 50% of revenue growth recently, appealing to US investors via exposure to healthcare digitization.

Why Pro Medicus Ltd matters for US investors

Pro Medicus offers US investors indirect exposure to the $50B+ radiology IT market, fueled by AI adoption and hospital consolidations. Its Visage platform is deployed at top US centers like Mass General, per company disclosures. With ASX listing, it's accessible via US brokers, tying into American healthcare spending trends.

Conclusion

Pro Medicus Ltd stands out in medical imaging software with its AI-enhanced Visage platform and expanding US footprint. Growth in contracts underscores demand, though execution in competitive markets remains key. Investors monitor healthcare tech trends for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.